Danaher Corp. (Danaher (DHR)) had a bit of a Jekyll-and-Hyde moment on Tuesday. The life sciences and diagnostics company reported second-quarter results that beat Wall Street's expectations on both earnings and revenue. But instead of celebrating, investors sent the stock down more than 14%. The culprit? A trimmed forecast for the rest of the year.

Let's start with the good news. Danaher posted adjusted earnings of $1.94 per share, easily topping the analyst consensus of $1.83. Revenue came in at $6.27 billion, up 5.5% from a year ago and ahead of the $6.10 billion estimate. Core revenue — which strips out acquisitions, divestitures, and currency effects — grew 3% year over year, right in line with management's guidance for low-single-digit growth. Exclude respiratory testing revenue, and core growth was 4.5%.

CEO Rainer Blair highlighted that the Life Sciences segment had its best quarter in several years. "While customer project timing impacted bioprocessing revenue, underlying order trends remained strong, and bioprocessing orders grew mid-teens in the quarter," Blair said. Biotechnology revenue rose 4% to $1.92 billion, Life Sciences revenue climbed 5.5% to $1.88 billion, and Diagnostics revenue increased 7% to $2.47 billion. Blair noted that continued end-market recovery and momentum from recent growth initiatives support the company's expectation to exit 2026 with mid-single-digit core revenue growth.

So why the sell-off? The market's focus was squarely on the outlook. Danaher lowered its fiscal 2026 core revenue growth forecast to 3% to 4%, down from its previous range of 3% to 6%. For the third quarter, the company expects non-GAAP core revenue growth of just 2% to 3% year over year, including a low-single-digit headwind from respiratory testing revenue. The Life Sciences segment is expected to see stronger growth than previously anticipated, but the Bioprocessing business — a key driver — is now expected to grow at a mid-single-digit rate, down from the prior expectation of high-single-digit growth.

Investors hate uncertainty, and a narrower, lower revenue forecast is rarely a crowd-pleaser. The stock dropped 14.57% to $171.80 by Tuesday's close.

There was one bright spot in the guidance: Danaher raised its full-year adjusted earnings forecast to a range of $8.45 to $8.60 per share, up from $8.35 to $8.55. The new range brackets the analyst consensus of $8.45. So the company is making more money per share, just on less revenue growth. That's the kind of math that can work for shareholders over time, but it wasn't enough to offset the revenue growth disappointment on Tuesday.

For retail investors, the takeaway is that Danaher's core business is still performing well, especially in Life Sciences. But the Bioprocessing slowdown is a real headwind, and the market is pricing in that caution. Whether the stock bounces back will depend on whether those mid-teens order growth numbers translate into actual revenue in the coming quarters.